Sanofi SA SASY.PA:
* NEW PHASE II RESULTS RELATING TO AMLITELIMAB CONFIRM ITS POTENTIAL AS BEST-IN-CLASS DRUG IN TERMS OF MAINTAINING RESPONSE IN THE TREATMENT OF ATOPIC DERMATITIS
*BREAKING DATA PRESENTED AT AAD CONGRESS SHOWS SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS OF ATOPIC DERMATITIS OFF TREATMENT WITH AMLITELIMAB FOR 28 WEEKS
*THE SAFETY PROFILE FOR PATIENTS TREATED THROUGH WEEK 52 WAS CONSISTENT WITH DATA COLLECTED AT WEEK 24; AMLITELIMAB WAS WELL TOLERATE AND NO NEW SAFETY SIGNALS WERE IDENTIFIED
* THE DURABILITY OF THE RESPONSE TO TREATMENT SUPPORTS THE INTEREST OF A QUARTERLY DOSAGE, CURRENTLY STUDIED AS PART OF A PIVOT PHASE III PROGRAM
* SUSTAINED REDUCTION OF BIOMARKERS Suggests that INHIBITION OF OX40L – A MECHANISM WITHOUT DEPLETING EFFECT ON T-LYMPHOCYTES – MODULATES THE IMMUNE RESPONSE AND PROVIDES LONG-LASTING DISEASE CONTROL
Original text on Eikon For more details, click on SASY.PA
(Gdańsk editorial office)